Dr Aviral Singh

Dr Aviral Singh
MD PGDipCard MSc FAfNM, Clinical Research and Development Manager

Theranostics provides a comparatively safer, targeted & individualised option for the management of cancer patients.

Languages spoken

English, Hindi, Deutsch, Russian

Expert in

Prostate cancer



North Shore
North Shore

North Shore Health Hub, Tower A, Level 1, 7 Westbourne Street, St Leonards NSW 2065, Australia

-33.82024297423824, 151.19062046149045

Specialises in

Prostate cancer
Condition/Cancer/Prostate Cancer



Special clinical interest in Theranostics of prostate cancer, neuroendocrine neoplasms, and other difficult-to-treat cancers.

Dr Aviral Singh is a Specialist Physician in Nuclear Medicine currently working as Clinical Research and Development Manager – Theranostics at GenesisCare Australia. He has relocated from Germany, where he was working as a Consultant Physician in Nuclear Medicine & Theranostics and Clinical Research Physician at the world-renowned ENETS Center of Excellence, Zentralklinik Bad Berka.

Following graduation in medicine from Ukraine, he acquired clinical training in nuclear medicine, intensive care and internal medicine from Germany, Australia and United Kingdom in English, German and Russian languages.

Aviral gained the degree of M.Sc. in Nuclear Medicine from King’s College London, University of London, UK in 2015, and is pursuing PhD from Maastricht University, Netherlands.

He has extensive clinical and research experience in Theranostics for the management of Neuroendocrine Neoplasms and Prostate Cancer.

Aviral is well-published with over 45 peer reviewed scientific papers in reputed medical journals and over 100 scientific abstracts presented at various international medical societies globally. His ResearchGate H-Index is 21. He has participated as a Clinical Investigator in multicentre clinical trials, such as the NETTER-1 and COMPETE.

With keen interest in medical education, Aviral has been invited as Guest Faculty and Invited Lecturer by several reputed international medical societies including ESMO, ENETS, ESO, COSA, WFNMB, and WARMTH.

Since 2018 Aviral is the elected Treasurer and Member of the Executive Board of the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH).

He is the member of the Topics Editorial Board of the journal Cells and is a regular peer reviewer for several reputed journals in the field of Theranostics.


  • Invited Faculty – European Neuroendocrine Tumor Society (ENETS) 9th Postgraduate course, Barcelona, Spain, March 2019
  • Invited Faculty - Preceptorship in Neuroendocrine Neoplasms – European Society of Medical Oncology (ESMO), Lugano, Switzerland, April 2018
  • Enlisted in The Leading Physicians of the World of 2017 edition of The International Association of HealthCare Professionals
  • Guest Speaker for keynote lecture on peptide receptor radionuclide therapy in neuroendocrine tumors at the ‘György Hevesy’ Hungarian Society of Nuclear Medicine 2017, Budapest, Hungary
  • First place for scientific poster in clinical oncology, Society of Nuclear Medicine and Molecular Imaging 2016, San Diego, CA, USA

Professional memberships

  • Treasurer and Executive Board Member, World Association of Radiopharmaceutical and Molecular Therapy
  • Member, Therapy Center of Excellence of the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
  • Member, Center for Molecular Imaging Innovation and Translation of the SNMMI
  • Member, European Neuroendocrine Tumor Society
  • Member, European Society of Medical Oncology


  • Feasibility, Biodistribution and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy (PTRT) of Diverse Adenocarcinomas using 177Lu-FAP-2286: First-in-Human Results. Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. J Nucl Med. 2021 Jun 24:jnumed.120.259192. doi: 10.2967/jnumed.120.259192. Online ahead of print.
  • From Bench to Bedside-The Bad Berka Experience with First-in-Human Studies. Zhang J, Singh A, Kulkarni HR, Schuchardt C, Müller D, Wester HJ, Maina T, Rösch F, van der Meulen NP, Müller C, Mäcke H, Baum RP. Semin Nucl Med. 2019 Sep;49(5):422-437. doi: 10.1053/j.semnuclmed.2019.06.002. Epub 2019 Jul 6.
  • Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. J Nucl Med. 2019 Jul;60(7):955-962. doi: 10.2967/jnumed.118.216820. Epub 2019 Jan 25.
  • 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. Baum RP, Singh A, Schuchardt C, Kulkarni HR, Klette I, Wiessalla S, Osterkamp F, Reineke U, Smerling C. J Nucl Med. 2018 May;59(5):809-814. doi: 10.2967/jnumed.117.193847. Epub 2017 Oct 12.
  • First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44Sc-DOTATOC: A Proof-of-Concept Study. Singh A, van der Meulen NP, Müller C, Klette I, Kulkarni HR, Türler A, Schibli R, Baum RP. Cancer Biother Radiopharm. 2017 May;32(4):124-132. doi: 10.1089/cbr.2016.2173.

Click here for publications list.